One of the most dreaded feelings for an investor is when the stock they just bought is overvalued, or they missed out on an undervalued opportunity by not acting fast enough.

But what if you had the insights to effectively evaluate a company like Myriad Genetics, Inc. before investing? Investing requires a certain perspective to avoid being overly confident in a company or worried about cyclical changes. A smart way to take the guesswork out of knowing when to buy or sell Myriad Genetics, Inc.’s stock is to have the right tools and resources as well as a clear monitoring process.

In this article, we go over a few key elements for understanding Myriad Genetics, Inc.’s stock price such as:

• Current stock price and volume
• Stock price history
• Upgrades and downgrades from analysts
• Stock price momentum as measured by its relative strength

About Myriad Genetics, Inc. (MYGN)

Before we jump into Myriad Genetics, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company primarily provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing the disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to ensure optimal treatment, or assess a patient’s risk of disease progression, and includes corporate services, such as finance, human resources, legal and information technology. The Company discovers and commercializes genetic tests. The Company's products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, EndoPredict, Foresight and Prequel, GeneSight, Vectra. The Company offers SneakPeek Early Gender DNA Test, which reveals a baby’s gender at six weeks into pregnancy. Its wholly owned subsidiaries include Myriad Genetic Laboratories, Inc., Assurex Health, Inc. and Myriad Women’s Health, Inc.

Want to learn more about Myriad Genetics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Myriad Genetics, Inc.. The AAII Stock Evaluator puts a company’s grades, charts, news, financials, valuation, ratios, filings and more at your fingertips.

Myriad Genetics, Inc.’s Stock Price as of Market Close

As of February 21, 2023, 4:00 PM CST, Myriad Genetics, Inc.’s stock price was $18.18.

Myriad Genetics, Inc. is down 6.39% from its previous closing price of $19.42.

During the last market session, Myriad Genetics, Inc.’s stock traded between $18.48 and $19.44. Currently, there are 80.70 million shares of Myriad Genetics, Inc. stock available for purchase.

Unfortunately, Myriad Genetics, Inc.’s P/E ratio is not significant enough to use for stock price evaluation. We recommend investors evaluate other financial metrics to understand its overall valuation.

Myriad Genetics, Inc. Stock Price History

Myriad Genetics, Inc.’s (MYGN) price is currently down 7.81% so far this month.

During the month of February, Myriad Genetics, Inc.’s stock price has reached a high of $21.40 and a low of $18.16.

Over the last year, Myriad Genetics, Inc. has hit prices as high as $28.18 and as low as $13.92. Year to date, Myriad Genetics, Inc.’s stock is down 34.13%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Myriad Genetics, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

One of the most common factors that can drastically impact a stock’s price is analyst upgrades and downgrades. When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of February 17, 2023, there was 1 analyst who downgraded Myriad Genetics, Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Myriad Genetics, Inc.’s financial health and valuation. It is possible for a stock to appear cheap based on one valuation metric but appear expensive on another. It is also possible for one valuation ratio to be associated with outperforming stocks during certain periods of time but not others.

Therefore, AAII developed a composite valuation to help resolve such issues. AAII’s Value Grade analyzes six distinct variables: price-to-sales (P/S) ratio, price-earnings (P/E) ratio, the ratio of enterprise value to earnings before interest, taxes, depreciation and amortization (EV/EBITDA), shareholder yield, price-to-book-value (P/B) ratio and price-to-free-cash-flow (P/FCF) ratio.

Myriad Genetics, Inc.’s current valuation based on AAII’s Value Grade is a D, which means it is considered to be Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Myriad Genetics, Inc. (MYGN) by visiting AAII Stock Evaluator.

Relative Price Strength of Myriad Genetics, Inc.

Relative price strength addresses the relationship between a stock price’s trend and the price trend of the market. This ratio is expressed as a percentage and helps investors understand a company’s momentum as well as its value. You can use relative price strength to select investments that have been outperforming the market or a specific benchmark.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. The weighted four-quarter relative price strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40%, and each of the three previous quarters are given a weighting of 20%.

As of February 17, 2023, Myriad Genetics, Inc. has a weighted four-quarter relative price strength of -4.02%, which translates to a Momentum Score of 33 and is considered to be Weak.

Want to learn more about how Myriad Genetics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Myriad Genetics, Inc. Stock Price: Bottom Line

As of February 21, 2023, Myriad Genetics, Inc.’s stock price is $18.18, which is down 6.39% from its previous closing price.

At AAII, we stress that investors should never buy or sell a stock solely based on its stock price. Past returns do not guarantee future performance. Therefore, you should consider multiple ratios, fundamentals and analytics before making a decision. Whether you decide it’s a good time to buy or sell Myriad Genetics, Inc.’s stock based on its stock price forecast is ultimately up to you.

It’s important to understand that stock prices are driven by a variety of factors, but ultimately the price at any given moment is due to the supply and demand in the market. Stock price overviews, like the one you just read, only give you a small snapshot of a company’s performance, value and momentum.

By becoming an A+ Investor subscriber, you will have full access to analytics, grades, stock screens, commentary and more so you can invest with confidence.